We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma (PROCLIVITY 02)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01856023
Recruitment Status : Terminated (A shift in the melanoma treatment landscape adversely affected accrual & early closure)
First Posted : May 17, 2013
Last Update Posted : July 17, 2015
Sponsor:
Collaborators:
M.D. Anderson Cancer Center
Johns Hopkins University
Information provided by (Responsible Party):
Prometheus Laboratories

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Primary Completion Date : July 2015
  Study Completion Date : July 2015